Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LisDexStudy: Lisdexamfetamine vs d-Amphetamine in Healthy Subjects
NCT02668926Phase 1Completed
- Sponsor
- University Hospital Basel
- Start
- May 2016
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lisdexamfetamine in attention deficit hyperactivity disorder (ADHD) (3 arms), sponsored by University Hospital Basel. Primary endpoints: Effects of lisdexamphetamine and d-Amphetamine on circulating steroidal hormones at 13 hours and Subjective effects of lisdexamphetamine and d-amphetamine at 13 hours. Started May 2016; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02668926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02668926.